Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.35 |
| ▸ | FPR1 | P21462 | 3/20 | 0.34 |
| ▸ | FPR2 | P25090 | 3/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 5/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618690 | 0.84 | PIK3CD (0.35) | PIM2FPR1FPR2LRRK2UCHL1 | |
| SCHEMBL17618668 | 0.82 | CHRM4 (0.36) | PIM2LRRK2DPP4UCHL1PIM1 | |
| SCHEMBL17618651 | 0.81 | FAAH (0.37) | PIM2FPR1FPR2LRRK2DPP4 | |
| SCHEMBL17618660 | 0.81 | HTR2C (0.43) | PIM2PIM1PIM3 | |
| SCHEMBL17618672 | 0.80 | PIM2 (0.38) | PIM2LRRK2DPP4UCHL1USP30 | |
| SCHEMBL17618667 | 0.80 | PIM2 (0.37) | PIM2FPR1FPR2LRRK2DPP4 | |
| SCHEMBL17618658 | 0.79 | PIM2 (0.37) | PIM2FPR1FPR2LRRK2UCHL1 | |
| SCHEMBL17618662 | 0.79 | FAAH (0.39) | PIM2LRRK2DPP4 | |
| SCHEMBL17618710 | 0.69 | PIM2 (0.40) | PIM2PIM1PIM3 | |
| SCHEMBL17618726 | 0.68 | ALDH1A1 (0.42) | PIM2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIM2 3242/4885FPR1 2573/4885FPR2 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.